Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)

European Journal of Cancer

Volumn 49, Issue 15, 2013, Pages 3242-3246

  Thielen, Noortje ^a   Van Der Holt, Bronno ^b   Cornelissen, Jan J ^c   Verhoef, Gregor E G ^d   Gussinklo, Titia ^b   Biemond, Bart J ^e   Daenen, Simon M G ^f   Deenik, Wendy ^g   Van Marwijk Kooy, Rien ^g   Petersen, Eefke ^h   Smit, Willem M ⁱ   Valk, Peter J M ^c   Ossenkoppele, Gert J ^a   Janssen, Jeroen J W M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g Tergooiziekenhuizen ^*  (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Chronic myeloid leukaemia; Complete molecular response; Discontinuation; Imatinib

Indexed keywords

CYTARABINE; IMATINIB; NILOTINIB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

CHRONIC MYELOID LEUKAEMIA; COMPLETE MOLECULAR RESPONSE; DISCONTINUATION; IMATINIB;

BELGIUM; BENZAMIDES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84884908539     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.018     Document Type: Article

References (21)

1. T.P. Hughes, J. Kaeda, and S. Branford Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423 1432
2. M. Deininger, S. O'Brien, and F. Guilhot International randomized study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib Blood 114 2009 Abstract 1126
3. P. Rousselot, F. Huguet, and D. Rea Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood 109 2007 58 60
4. D.M. Ross, S. Branford, and J.F. Seymour Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR Leukemia 24 2010 1719 1724
5. F.X. Mahon, D. Rea, and J. Guilhot Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 11 2010 1029 1035
6. N. Takahashi, T. Kyo, and Y. Maeda Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia Haematologica 97 2012 903 906
7. J. Cortes, S. O'Brien, and H. Kantarjian Discontinuation of imatinib therapy after achieving a molecular response Blood 104 2004 2204 2205
8. S. Merante, E. Orlandi, and P. Bernasconi Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation Haematologica 90 2005 979 981
9. H.Y. Yhim, N.R. Lee, and E.K. Song Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response Leuk Res 36 2012 689 693
10. W. Deenik, B. van der Holt, and G.E. Verhoef Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia Blood 111 2008 2581 2588
11. W. Deenik, J.J. Janssen, and B. van der Holt Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia Haematologica 95 2010 914 921
12. T. Hughes, M. Deininger, and A. Hochhaus Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 2006 28 37
13. M. Ross, S. Branford, and J. Seymour Frequent and sustained drug-free remission in the Australasian CML8 trial of imatinib withdrawal Haematologica 97 s1 2012 Abstract 0189
14. F.X. Mahon, X. Delbrel, and P. Cony-Makhoul Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa J Clin Oncol 20 2002 214 220
15. A. Burchert, M.C. Muller, and P. Kostrewa Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia J Clin Oncol 28 2010 1429 1435
16. C. Preudhomme, J. Guilhot, and F.E. Nicolini Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia N Engl J Med 363 2010 2511 2521
17. M. Deininger Hematology: curing CML with imatinib - a dream come true? Nat Rev Clin Oncol 8 2011 127 128
18. S.M. Graham, H.G. Jorgensen, and E. Allan Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 2002 319 325
19. M. Copland, A. Hamilton, and L.J. Elrick Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction Blood 107 2006 4532 4539
20. H.G. Jorgensen, E.K. Allan, N.E. Jordanides, J.C. Mountford, and T.L. Holyoake Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells Blood 109 2007 4016 4019
21. S. Chu, T. McDonald, and A. Lin Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment Blood 118 2011 5565 5572